Blog Coverage Pfizer Reported Positive Results for Mid-stage Trial for C. difficile Vaccine

Upcoming AWS Coverage on Impax Laboratories Post-Earnings Results

LONDON, UK / ACCESSWIRE / January 27, 2017 / Active Wall St. blog coverage looks at the headline from Pfizer Inc. (NYSE: PFE) as the Company announced on January 26, 2017, that the Phase-2 study evaluating the Company’s Clostridium difficile (C. difficile) vaccine candidate, PF-06425090, provided positive data, based on a pre-planned interim analysis. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Pfizer’s competitors within the Drug Manufacturers – Major space, Impax Laboratories, Inc. (NASDAQ: IPXL), announced on January 25, 2017, that the Company will release its Q4 and full year 2016 financial results on Wednesday, March 01, 2017, prior to the open of the US financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. ET on March 01, 2017. AWS will be initiating a research report on Impax Laboratories in the coming days.

Today, AWS is promoting its blog coverage on PFE; touching on IPXL. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=PFE

http://www.activewallst.com/registration-3/?symbol=IPXL

The Phase-2 Study

Pfizer stated that the randomized Phase-2 study (NCT02561195) was placebo-controlled, and observer-blinded study of more than 850 healthy adults 65-85 years of age, evaluating the safety, tolerability, and immunogenicity of two dose levels (100 µg and 200 µg) of Pfizer’s C. difficile vaccine candidate on two different three-dose vaccination schedules. Pfizer’s vaccine candidate is designed to help prevent C. difficile infection (CDI), which can include life-threatening diarrhea and pseudomembranous colitis, by inducing a functional antibody response capable of neutralizing the two main disease-causing toxins produced by C. difficile.

Kathrin Jansen, Ph.D., senior vice president and head of Vaccine Research and Development for Pfizer Inc. stated:

“We are very encouraged by these interim immunogenicity and safety results demonstrating robust increases in vaccine-elicited neutralizing antibodies to both toxins, that we believe could provide protection against C. difficile disease.”

Based on findings from the pre-planned interim analysis, Pfizer’s C. difficile vaccine candidate will progress into Phase-3 in H1 2017. Pfizer’s C. difficile vaccine candidate was granted Fast Track designation by the US Food and Drug Administration (FDA) in August 2014. The FDA’s Fast Track designation is designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address an unmet medical need.

About Clostridium difficile

C. difficile is a spore-forming pathogen that typically causes symptoms in individuals with altered gut microbial flora, releasing toxins that can result in a range of disease manifestations from asymptomatic colonization to diarrhea, pseudomembranous colitis, toxic megacolon, intestinal perforation, or, in the most severe cases, death.

Pfizer noted that C. difficile, classified by the US Centers for Disease Control and Prevention (CDC) as an urgent public health threat in 2013, is the most common cause of antibiotic-associated diarrhea in the healthcare setting and an increasing concern worldwide. The disease was responsible for approximately 453,000 US cases (associated with 29,000 deaths) in 2011. CDI disproportionately affects older adults, with nearly two-thirds of cases in patients over the age of 65. The Company noted that current treatment options may offer temporary therapeutic improvements, but will not provide long-term protection. Up to 25% of patients treated for a first episode of CDI experience a first recurrence of infection, and up to 65% of those patients who experience a first recurrence will experience multiple recurrences.

Stock Performance

On Thursday, January 26, 2017, Pfizer’s shares were slightly down 0.03% from its previous closing price of $31.29, finishing the day at $31.28. A total volume of 27.18 million shares were traded at the end of the day. In the previous twelve months, the stock gained 6.37%. Shares of the company have a PE ratio of 31.22 and have a dividend yield of 4.09%. The stock currently has a market cap of $189.74 billion.

Earnings Alert: Pfizer will report its Q4 2016 financial results on January 31, 2017.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 453670